Breaking Finance News

Allergan Inc. (NYSE:AGN) stock price target reduced to $250.00, issued a research note today by RBC Capital Markets

Yesterday Allergan Inc. (NYSE:AGN) traded -5.37% lower at $189.62. The company’s 50-day moving average is $213.47 and its 200-day moving average is $231.01. The last closing price is down -18.99% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 13,761,365 shares of AGN traded hands, up from an average trading volume of 2,672,830

In a report released on Thursday October 19, 2017 RBC Capital Markets reduced the stock price target of Allergan Inc. (NYSE:AGN) from $277.00 to $250.00 indicating a possible upside of 0.32%.

Previously on 10/17/2017, UBS Securities reported on Allergan Inc. (NYSE:AGN) reduced the target price from $275.00 to $255.00. At the time, this indicated a possible upside of 0.26%.

Recent Performance Chart

Allergan Inc. (NYSE:AGN)

Allergan Inc. has 52 week low of $184.50 and a 52 week high of $256.80 with a P/E ratio of 5.70 and has a market cap of $0.

In addition to RBC Capital Markets reporting its target price, a total of 16 firms have reported on the stock. The consensus target price is $293.75 with 7 firms rating the stock a strong buy, 11 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Allergan Inc. (NYSE:AGN)

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.